Adcendo

Adcendo is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for treating underserved cancers. Their focus is on first-in-class ADCs to address cancers with high unmet medical needs. The company aims to significantly change treatment paradigms through its innovative ADC pipeline.

Funding Round: Series B

Funding Amount: $135M

Date: 25-Nov-2024

Investors: TCGX, TPG Life Sciences Innovations, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital, Logos Capital, RA Capital Management, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, KKR, HealthCap, Gilde Healthcare, Ysios Capital

Markets: Biotechnology, Oncology, Pharmaceuticals, Biotechnology Research

HQ: Frederiksberg, Capital Region of Denmark, Denmark

Founded: 2017

Website: https://www.adcendo.com/

LinkedIn: https://www.linkedin.com/company/adcendo/

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/adcendo

Pitchbook: https://pitchbook.com/profiles/company/303080-50